Formulation and Physicochemical Characterization of Magnetic Nanoparticles Containing Brimonidine for Ophthalmic Drug Delivery by Afsharipour, Sepehr et al.
 
Pharmacy Updates 2018 
 
Formulation and Physicochemical Characterization of Magnetic Nanoparticles 
Containing Brimonidine for Ophthalmic Drug Delivery  
Sepehr Afsharipour 
a
, Abbas Pardakhty  
a,b
 , Maryam Kazemipour 
c
  , Neda Ahmadi 
a







 School of Pharmacy, Kerman 
Medical University, Kerman, Iran. 
 
 b
 Pharmaceutics Research Center, 
Neuropharmacology Institute, 
Kerman University of Medical 




Kerman Branch, Islamic Azad 
University, Kerman, Iran 
 
Abstract Presenter: 
Sepehr Afsharipour; Pharmacy 
Student, Faculty of Pharmacy and 
Pharmaceutical Siences, Kerman 






Mehdi Ansari ,PhD, 
Department of Pharmaceutics , 
Faculty of Pharmacy and 
Pharmaceutical Sciences Kerman 







Introduction: Recently, magnetic nanoparticles (MNPs) drew a great attention for 
application in drug delivery systems. Due to their biocompatibility and non-toxic 
properties, they have potential to create versatile drug delivery systems. Brimonidine 
(a relatively selective alpha-2 adrenergic receptor agonist) has a significant effect on 
lowering intraocular pressure in glaucoma. In this study MNPs were coated with 
alginate and chitosan and loaded by brimonidine to prepare a drug delivery system 
applicable in glaucoma treatment. 
Methods and Results: Brimonidine, sodium alginate and MNPs have been prepared 
as a dispersion. Chitosan solution was added dropwise to the previous dispersion. 
The dispersion was centrifuged and the absorbance of the supernatant analyzed by 
UV spectrophotometer at the λmax of 246 nm. The final dispersion was freeze-dried. 
The morphological studies of chitosan alginate MNPs(C-A-MNPs) have been done 
by using transmission electronic microscope (TEM). The release rate of brimonidine 
tartrate was evaluated by Franz diffusion cell through cellophane membrane. 
Results showed that more than 93% of the brimonidine tartrate was loaded on the C-
A-MNPs. The formulation prepared was stable at room temperature protected from 
light. Release study showed that less than 40% of the brimonidine was released after 
2 hours compared to simple formulation of brimonidine solution which showed more 
than 80% release after 2 hours. This finding showed sustained release in C-A-MNPs 
formulation. Kinetic of drug release from C-A-MNPs was slower than blank and 
followed zero order. The stability of formulation was more than 2 years. 
Conclusions: 
It can be concluded that loading of brimonidine on C-S-MNPs may decrease the 
frequency of administration and increase the efficacy of the product.  
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